280 related articles for article (PubMed ID: 37834929)
1. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.
Shah M; Awad AS; Abdel-Rahman EM
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834929
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
3. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
Georgianos PI; Agarwal R
Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
[TBL] [Abstract][Full Text] [Related]
4. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
5. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.
Palanisamy S; Funes Hernandez M; Chang TI; Mahaffey KW
Cardiol Ther; 2022 Sep; 11(3):337-354. PubMed ID: 35737275
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
Beavers CJ
Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
[TBL] [Abstract][Full Text] [Related]
9. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
10. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.
Arici M; Altun B; Araz M; Atmaca A; Demir T; Ecder T; Guz G; Gogas Yavuz D; Yildiz A; Yilmaz T
Front Med (Lausanne); 2024; 11():1384454. PubMed ID: 38947237
[TBL] [Abstract][Full Text] [Related]
11. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction.
Kintscher U; Edelmann F
Cardiovasc Diabetol; 2023 Jun; 22(1):162. PubMed ID: 37386461
[TBL] [Abstract][Full Text] [Related]
12. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
15. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
[TBL] [Abstract][Full Text] [Related]
17. Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
[TBL] [Abstract][Full Text] [Related]
18. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]